

Fast Facts

Founded: 2000
IPO: December 2, 2014
Ticker: HSGX
Exchange: NASDAQ
Employees: ~50

Recent Milestones

Q2: 2017
 Confirmation of development and regulatory requirements with Japan PMDA

Q2: 2017
 Completion of enrollment in Phase 3 clinical trial

Q4: 2017
 Development and commercialization rights to NeoCart in Japan licensed to MEDINET Co. Ltd.

Q3: 2018
 NeoCart top-line Phase 3 data announced

About Histogenics


Histogenics is a leader in the development of restorative cell therapies (RCT) that may offer rapid-onset pain relief and restored function in patients with orthopedic conditions.

Restorative Cell Therapy Platform

Histogenics' Restorative Cell Therapy (RCT) platform uses an array of proprietary biotech processes and combines breakthroughs in bio-engineering, biomaterials and cell processing to enhance the autologous cartilage repair process. The resulting RCT is functional living cartilage at the time of treatment.


Our first RCT product candidate, NeoCart[®], potentially rebuilds a patient's own knee cartilage for rapid onset pain relief and restored function and may delay or prevent osteoarthritis. With a large and growing market in knee cartilage damage, there is a critical need for a novel therapy, such as NeoCart, that is designed to treat pain and get patients back to work and daily activities more rapidly than the current alternatives.

The RCT platform has the potential to be used for a broad range of additional indications, including cartilage for other joints, as well as other tissue types.




NeoCart[®]

Histogenics' lead product candidate, NeoCart[®], rebuilds patients' knee cartilage to treat pain at the source and to potentially delay or prevent the progression to osteoarthritis. In clinical trials to date, NeoCart, a rigorously studied personalized restorative cell therapy for orthopedic use, demonstrated improved pain relief and return to function in about half the time compared to the standard of care, microfracture.



The NeoCart Phase 3 clinical trial is believed to be the largest and first prospectively designed, randomized clinical trial in North America evaluating the safety and efficacy of a restorative cell therapy to treat knee cartilage damage in 249 adults. The Phase 3 clinical trial was conducted under a SPA agreement with the U.S. Food and Drug Administration (FDA). Study enrollment was completed in Q2 2017 and top-line one-year data announced in Q3 2018.

Path to Commercialization & Launch



Leadership

Adam Gridley

Chief Executive Officer & President

Don Haut

Chief Business Officer

E. Lynne Kelley

Chief Medical Officer

Jon Lieber

Chief Financial Officer

Stephen Kennedy

Chief Operating Officer

Board of Directors

Garheng Kong, M.D., Ph.D.

HealthQuest Capital

Josh Baltzell

SightLine Partners

David Gill

Chairman of the Audit Committee

John Johnson

Independent Board Member

Michael Lewis

Oceana Investment Partners

Adam Gridley

Histogenics

Kevin Rakin

High Cape Partners

Sue Washer

Applied Genetic Technology Corporation